ID
26406
Beskrivning
Study ID: 101468/190 Clinical Study ID: SKF-101468/190 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome This is the Serious Adverse Events assessment form.
Nyckelord
Versioner (1)
- 2017-10-17 2017-10-17 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
17 oktober 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Serious Adverse Events 26072_GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
Form D 26072_GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
Similar models
Form D 26072_GSK Ropinirole in Patients Suffering from Restless Legs Syndrome 101468/190
C0243095 (UMLS CUI [1,2])
C0004398 (UMLS CUI [1,3])
C0011900 (UMLS CUI [1,4])
C0011008 (UMLS CUI [1,2])